NYSE:RCUS Arcus Biosciences - RCUS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.24 +0.78 (+4.47%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$17.55▼$18.5150-Day Range$15.96▼$23.1552-Week Range$15.70▼$39.75Volume957,754 shsAverage Volume1.25 million shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$41.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arcus Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside126.6% Upside$41.33 Price TargetShort InterestHealthy14.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 3 Articles This WeekInsider TradingSelling Shares$153,802 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.52) to ($3.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector298th out of 1,004 stocksPharmaceutical Preparations Industry130th out of 489 stocks 3.4 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.33, Arcus Biosciences has a forecasted upside of 126.6% from its current price of $18.24.Amount of Analyst CoverageArcus Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted14.21% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Arcus Biosciences has recently decreased by 10.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RCUS. Previous Next 2.0 News and Social Media Coverage News SentimentArcus Biosciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Arcus Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $153,802.00 in company stock.Percentage Held by Insiders12.70% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.97% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to grow in the coming year, from ($4.52) to ($3.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcus Biosciences (NYSE:RCUS) StockArcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.Read More Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Stock News HeadlinesMarch 27, 2023 | finance.yahoo.comPrecision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks ConferenceMarch 23, 2023 | americanbankingnews.comInsider Selling: Arcus Biosciences, Inc. (NYSE:RCUS) COO Sells 8,729 Shares of StockApril 1, 2023 | The Oxford Club (Ad)Unusual Passive Income Investment (Found on a Golf Course)Marc reveals how anyone can get into a similar opportunity for just $5.March 23, 2023 | seekingalpha.comArcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 ResultsMarch 21, 2023 | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) Receives $40.50 Average Price Target from AnalystsMarch 19, 2023 | benzinga.comMizuho Reiterates Buy on Arcus Biosciences, Maintains $51 Price TargetMarch 19, 2023 | benzinga.comArcus Biosciences Stock (NYSE:RCUS), Short Interest ReportMarch 16, 2023 | markets.businessinsider.comMizuho Securities Sticks to Its Buy Rating for Arcus Biosciences (RCUS)April 1, 2023 | Investorplace Media (Ad)5 Hypergrowth Stocks to Buy NowLuke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. March 9, 2023 | finance.yahoo.comPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business UpdateMarch 6, 2023 | finance.yahoo.comKALA Q4 Loss Wider Than Expected, Pipeline Remains in FocusMarch 3, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Arcus Biosciences (RCUS)March 3, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Arcus Biosciences (RCUS)March 2, 2023 | finance.yahoo.comArcus Biosciences to Participate in the Barclays Global Healthcare ConferenceMarch 1, 2023 | finance.yahoo.comArcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline UpdateMarch 1, 2023 | finance.yahoo.comArcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue EstimatesFebruary 24, 2023 | finance.yahoo.comPrecision BioSciences Announces Senior Leadership Promotions and Organizational ChangesFebruary 21, 2023 | marketwatch.comImmuno-oncology Therapy Market Size 2023 With Strong Supplier, Key Factors, Driving The Market Growth, Information 2027February 17, 2023 | finance.yahoo.comAlkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock UpFebruary 15, 2023 | finance.yahoo.comZacks.com featured highlights include Arcus Biosciences, Suzano and Arch ResourcesFebruary 9, 2023 | marketwatch.comTIGIT Therapies Market to Grow Exponentially Due to Rising DemandFebruary 7, 2023 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)February 6, 2023 | finance.yahoo.comArcus Biosciences to Participate at Upcoming Virtual Investor EventsFebruary 3, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Hold Rating on Arcus Biosciences (RCUS)February 2, 2023 | seekingalpha.comRoche CEO drags Arcus, iTeos lower after comments on cancer trialJanuary 30, 2023 | finance.yahoo.comGSK Gears Up to Report Q4 Earnings: What's in the Cards?January 23, 2023 | finance.yahoo.comAmarin Corporation (AMRN) Down 13% in One Week: Here's WhySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Company Calendar Last Earnings11/08/2021Today4/01/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:RCUS CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees366Year FoundedN/APrice Target and Rating Average Stock Price Forecast$41.33 High Stock Price Forecast$51.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+126.6%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-267,000,000.00 Net Margins-237.26% Pretax Margin-237.50% Return on Equity-36.77% Return on Assets-18.51% Debt Debt-to-Equity RatioN/A Current Ratio5.53 Quick Ratio5.53 Sales & Book Value Annual Sales$112 million Price / Sales11.89 Cash FlowN/A Price / Cash FlowN/A Book Value$9.07 per share Price / Book2.01Miscellaneous Outstanding Shares73,010,000Free Float63,739,000Market Cap$1.33 billion OptionableOptionable Beta0.89 Key ExecutivesTerry J. RosenChairman & Chief Executive OfficerJuan Carlos JaenPresident & DirectorJennifer A. JarrettChief Operating Officer & DirectorRobert C. GoeltzChief Financial OfficerSteve YoungSenior VP-Technology & Quantitative BiologyKey CompetitorsRocket PharmaceuticalsNASDAQ:RCKTAgios PharmaceuticalsNASDAQ:AGIODynavax TechnologiesNASDAQ:DVAXViking TherapeuticsNASDAQ:VKTXDICE TherapeuticsNASDAQ:DICEView All CompetitorsInsiders & InstitutionsJennifer JarrettSold 8,729 sharesTotal: $146,734.49 ($16.81/share)Voya Investment Management LLCBought 2,170 shares on 2/28/2023Ownership: 0.040%Macquarie Group Ltd.Sold 758 shares on 2/21/2023Ownership: 0.524%Alliancebernstein L.P.Sold 151,466 shares on 2/16/2023Ownership: 1.222%Point72 Middle East FZEBought 2,781 shares on 2/16/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions RCUS Stock - Frequently Asked Questions Should I buy or sell Arcus Biosciences stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCUS shares. View RCUS analyst ratings or view top-rated stocks. What is Arcus Biosciences' stock price forecast for 2023? 9 brokerages have issued 12 month price targets for Arcus Biosciences' shares. Their RCUS share price forecasts range from $33.00 to $51.00. On average, they predict the company's stock price to reach $41.33 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price. View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts. How have RCUS shares performed in 2023? Arcus Biosciences' stock was trading at $20.68 at the beginning of the year. Since then, RCUS stock has decreased by 11.8% and is now trading at $18.24. View the best growth stocks for 2023 here. When is Arcus Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our RCUS earnings forecast. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings results on Monday, November, 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.13) by $0.02. The firm had revenue of $9.46 million for the quarter, compared to analysts' expectations of $9.27 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 36.77% and a negative net margin of 237.26%. During the same period in the prior year, the company posted $0.03 earnings per share. What ETFs hold Arcus Biosciences' stock? ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), First Trust Innovation Leaders ETF (ILDR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO? 4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD). When did Arcus Biosciences IPO? (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO. What is Arcus Biosciences' stock symbol? Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS." How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcus Biosciences' stock price today? One share of RCUS stock can currently be purchased for approximately $18.24. How much money does Arcus Biosciences make? Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.33 billion and generates $112 million in revenue each year. The company earns $-267,000,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. How many employees does Arcus Biosciences have? The company employs 366 workers across the globe. How can I contact Arcus Biosciences? Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com. This page (NYSE:RCUS) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.